Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2010 Jul;116(1):147-159.
doi: 10.1097/AOG.0b013e3181e45951.

Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis

Zhongjie Shi  1 , Yuebo Yang, Lin Ma, Xiaomao Li, Ann Schreiber
Affiliations
Meta-Analysis

Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis

Zhongjie Shi et al. Obstet Gynecol. 2010 Jul.

Erratum in

  • Obstet Gynecol. 2013 Feb;121(2 Pt 1):384

Abstract

Objectives: To evaluate efficacy of lamivudine in reducing in utero transmission of hepatitis B virus (HBV).

Data sources: A database was constructed from Medline, EMBASE, Cochrane Library, National Science Digital Library, China Biological Medicine Database, and through contact with experts in the field from January 1990 to October 2009.

Methods of study selection: We used the Jadad score and Cochrane Collaboration's tool for assessing risk of bias.

Tabulation, integration, and results: We abstracted data regarding HBV intrauterine infection, mother-to-child transmission, maternal HBV DNA level, treatment methods, and adverse effects. All newborns followed joint immune prophylaxis schedule of hepatitis B vaccine and hepatitis B immunoglobulin after delivery. The Mantel-Haenszel random-effects model was employed for all analyses using odds ratio (OR) and 95% confidence interval. Compared with the no-treatment group or placebo group, newborns in the lamivudine group had a 10.7–23.7% lower incidence of intrauterine infection, indicated by newborn hepatitis B surface antigen (0.38,0.15–0.94, six randomized controlled trials [RCTs], P5.04) and HBV DNA (0.22, 0.12–0.40, four RCTs, P,.001) seropositivity, and a 12.7–33.2% lower mother-to child transmission rate at 9–12 months, indicated by infant hepatitis B surface antigen (0.31, 0.15–0.63, five RCTs, P,.01) and HBV DNA (0.20, 0.10–0.39, two RCTs,P,.001) seropositivity [corrected].No significant higher adverse effects or complications in pregnancy were observed.

Conclusion: Lamivudine in HBV carrier-mothers with high degree of infectiousness in late pregnancy effectively prevented HBV intrauterine infection and mother-to-child transmission.

PubMed Disclaimer

References

    1. Merle P, Trepo C, Zoulim F. Current management strategies for hepatitis B in the elderly. Drugs Aging 2001;18:725–35.
    1. Hamdani-Belghiti S, Bouazzaou NL. Mother-child transmission of hepatitis B virus. State of the problem and prevention. Arch Pediatr 2000;7:879–82.
    1. Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. MMWR Recomm Rep 2006;55:1–33.
    1. Pongpipat D, Suvatte V, Assateerawatts A. Persistent HBsAg antigenemia in newborn infants following intrauterine HBV infection. Cause for the failure of the prevention of perinatal HBV transmission. Monatsschr Kinderheilkd. 1986;134:473–4.
    1. Guo Y, Liu J, Meng L, Miena H, Du Y. Survey of HBsAg-positive pregnant women and their infants regarding measures to prevent maternal-infantile transmission. BMC Infectious Diseases 2010;10:26.

MeSH terms